Cardiogenesis Corp /CA Form 8-K August 18, 2009

Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2009 CARDIOGENESIS CORPORATION

(Exact name of registrant as specified in its charter)

California 000-28288 77-0223740

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

11 Musick Irvine, CA 92618

(Address of principal executive offices, including zip code)
Registrant s telephone number, including area code: (949) 420-1800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

Item 2.02 Results of Operation and Financial Condition

Item 9.01 Financial Statements and Exhibits

SIGNATURE

Exhibit Index

EX-99.1

EX-99.2

Table of Contents

Item 2.02 Results of Operation and Financial Condition

On August 13, 2009, Cardiogenesis Corporation (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2009. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Also on August 13, 2009, the Company held a conference call with analysts and investors to report its financial results for the quarter ended June 30, 2009. The transcript of the conference call is furnished as Exhibit 99.2 and is incorporated herein by reference.

The information in this Form 8-K, including Exhibits 99.1 and 99.2, are furnished pursuant to Item 2.02 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
99.1	Press release of Cardiogenesis Corporation dated August 13, 2009.
99.2	Conference Call Transcript dated August 13, 2009.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARDIOGENESIS CORPORATION (Registrant)

Date: August 18, 2009 By: /s/ William Abbott

William Abbott, Chief Financial Officer

and Secretary

Table of Contents

Exhibit Index

Exhibit Number	Description
99.1	Press release of Cardiogenesis Corporation dated August 13, 2009.
99.2	Conference Call Transcript dated August 13, 2009.